BC Innovations | Nov 8, 2018
Emerging Company Profile

Abarceo: restoring beta cell function

Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments. Standard first-line therapy for Type...
Items per page:
1 - 1 of 1